Bravecto

RSS

fluralaner

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Bravecto. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Bravecto.

For practical information about using Bravecto animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 22/06/2018

Authorisation details

Product details
Name
Bravecto
Agency product number
EMEA/V/C/002526
Active substance
fluralaner
International non-proprietary name (INN) or common name
fluralaner
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53BE02
Publication details
Marketing-authorisation holder
Intervet International B.V
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
11/02/2014
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
NETHERLANDS

Product information

18/05/2018 Bravecto - EMEA/V/C/002526 - IB/0026

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ECTOPARASITICIDES FOR SYSTEMIC USE

Therapeutic indication

For the treatment of tick and flea infestations in dogs and cats.

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Assessment history

How useful was this page?

Add your rating